Pipeline

Debio 8206 Hormone-dependent Prostate Cancer, LHRH agonist Debio 8609, Sanvar® Esophageal variceal bleeding, Somatostatin analog Tremelimumab (codevelopment with Pfizer Inc.) Oncology, Monoclonal antibody Debio 025 (licenced to Novartis worldwide except Japan) HCV, Cyclophilin inhibitor Debio 0507 Oncology, Platinum micellar nanoparticles Debio 0827 Chronic pain, Enkephalinase inhibitor Debio 0932 Oncology, Hsp90 inhibitor Debio 0719 Oncology, LPA receptors antagonist Debio 0931 Oncology, CDC25 inhibitor Debio 0928 Oncology, Raf1-Rb inhibitor Debio 0617 Oncology, undisclosed target Debio 0930 Metabolic diseases, AMPK activator Debio 0826 Oncology, undisclosed target Debio 0721 Undisclosed target Debio 0929 Oncology, undisclosed target Debiopharm Group's projects cover all molecule type proteins, peptides, small molecules